The RacR business model includes internal research and development as well as partnerships with universities.

  • Vanderbilt University
    Exclusive access to Dr. Manning’s work at Vanderbilt University includes patents and patent applications for glutamine transporter inhibitors and imaging technology for tumors susceptible to our developed treatments.   The portfolio includes hundreds of compounds leading to drug and imaging candidates.
  • The University of Texas, MD Anderson Cancer Center.
    Dr. Manning and Team are now at The University of Texas, MD Anderson Cancer Center.
  • Colorado State University
    Exclusive rights to Ax-101 from Colorado State University.  Ax-101 has been through FIH trail and shown no significant adverse effects and anti tumor activity in halting all tumor growth and shrinking most.

  • VCOM

  • Gibbs Cancer Center

 

RaCR is in discussions with multiple researchers at a number of additional universities and projecting to continue to fill the pipeline of opportunities.